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A statement from the
National Institutes of
Health warned of the
dangers of performing
this experimental
procedure.
At the American
Heart Association’s
Scientific Session in
Orlando . . . a sym-
posium celebrating
the NHLBI Registry
was held.
The registry was
pivotal in setting a
benchmark for new
adopters in its first
iteration. . .
By comparing these
waves we can clearly
see the evolution of
the method. . .
Interventional cardi-
ology continues to
evolve and the
changes need to be
compared to what has
gone on before.DITOR’S PAGE
Valuable Public Option
hen we look back to the beginning of coronary interventions, those of us not chronologically
hallenged, are amazed at the evolution that has occurred. This is true for many endeavors, but
he process of that evolution is seldom chronicled prospectively as it has been for interventional
ardiology. When Andreas Gruentzig had done 100 cases in Zurich and the technique had
egun to be adopted in the U.S., a major concern arose. A statement from the National
nstitutes of Health warned of the dangers of performing this experimental procedure. “On the
asis of this early reported experience, it appears that PTCA has limited promise as a
herapeutic technique for a small number of categories of patients with obstructive coronary
isease. It also appears that this technique is technically demanding and involves a definite risk
f myocardial infarction and death even when used by skilled, experienced operators who are
areful to apply it only when appropriate. Caution against the use of this research technique
ithout such special experience and meticulous case selection should be evident.” (1). A
onference was called at the National Heart, Lung, and Blood Institute (NHLBI) stimulated
y Dr. Michael Mock. Several of the early adopters convened and conceived of a registry to
eep up with this “experimental technique.” The School of Public Health at the University of
ittsburgh became the data center under the direction of the late Dr. Katherine Detre.
ndreas was an enthusiastic supporter of this endeavor.
At the American Heart Association’s Scientific Session in Orlando (yesterday as I write
his), a symposium celebrating the NHLBI Registry was held. The program organized by Dr.
avid Williams reviewed the contributions of the NHLBI Registry, which the agency has
ontinued to support for 30 years. The first collection of the fledgling experience in 1979
eflected a success rate of 65%, with many patients opting for emergency surgery due to
omplications of the procedure. There is little wonder that there was concern that unbridled
roliferation could become a public health issue. The registry was pivotal in setting a
enchmark for new adopters in its first iteration from 1979 to 1981. By 1985, the progress in
ngioplasty, largely driven by improved devices and steerable guidewires, stimulated a second
ave of the registry. A third wave was necessary when many new devices of the late 1980s and
arly 1990s were introduced. Surprising to many of us, the new devices were shown to be not
s effective as balloon angioplasty, and with the exception of stents, most of them were
ropped from the tool box. Many of the original sites that participated in the registry
ontinued to collect the required detailed data and perform the meticulous follow-up
hroughout the subsequent registries. Since women were under-represented, a registry limited
o women was commissioned and showed important gender differences.
A common method was used in performing these registries. Approximately 15 hospitals
nrolled consecutive patients having percutaneous coronary intervention (PCI) until a cohort of
pproximately 2,000 cases was collected. These biopsies of the practice of PCI were continued
nder the name “Dynamic Registry.” Now more waves of that registry have studied the
utcome during the stent era and the drug-eluting stent era. By comparing these waves we can
learly see the evolution of the method in real time. Over 100 publications, many in the
eading journals, have led to extensive citations resulting from this important work. Young
nvestigators have developed a keen interest in outcomes research and over 150 unique
nvestigators have authored these manuscripts.
There are other registries that make major contributions, and each of them has different
apabilities to address important questions. Single-site registries, such as the Duke and Emory
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130atabases, can perform a longitudinal follow-up with their
wn patients. The New York State database has become a
enchmark for the country in studying very large
opulations of patients with systematic data collection
rom all laboratories in the state, and outcomes can be
ied to vital statistics data and administrative databases.
he American College of Cardiology (ACC), through the
ational Cardiovascular Data Registry (NCDR), has the
argest cardiac database with voluntary participation and
areful collection of hospital outcomes. Hopefully, future
egislation will enable longitudinal follow-up with unique
dentifiers. A recent federal grant will enable a
ollaborative outcomes study coupling the NCDR registry
nd the registry of the Society of Thoracic Surgeons.
ach registry has strengths that augment randomized
rials and extend observations well beyond those restricted
o randomized trial participants. Most of these
andomized trials in our field are very expensive and are
ndertaken by industry in order to gain Food and Drug
dministration approval and labeling. These are necessary
ut they often do not address the questions that are most
linically important to us and our patients.
At the 30-year celebration of the NHLBI registry, the
uture was a major point of discussion. Interventional
ardiology continues to evolve and the changes need to be
ompared to what has gone on before. Some coming
rends are structural heart disease interventions, left main
tenting (now a Class IIb indication in the 2009
merican College of Cardiology/American Heart
ssociation focused guideline update for ST-elevation MI
nd PCI [2]), radial access interventions with same-day
ischarge, and genomic variations and their impact onnterventions (personalized medicine), as well as numerousthers. Important questions regarding the performance
nd outcome of these procedures should not wait for an
conomic imperative of industry to be addressed. The
nswers are important for our patients and those treating
hem, as well as those paying for the care. Until now,
rivate payers have not contributed to these efforts. They
hould, as they would get a very big bang for their buck.
eanwhile, we can be thankful that the government has
tepped up for the past 30 years and enabled a talented
roup at the coordinating center, headed by Dr. Sheryl
elsey and a very small army of dedicated investigators
nd coordinators, to define the progress of interventional
ardiology, to identify some of its foibles, and to provide
bjective evidence of the value of our future endeavors.
ongratulations to all of you!
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